Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
Second quarter 2018 results and R&D update
On Wednesday 25 July we will announce our second quarter 2018 results for the period ended 30 June 2018 and give an update on R&D.
Latest information
Latest press releases
- US FDA Advisory Committee endorses the effectiveness and safety of single-dose tafenoquine for the radical cure of P. vivax malaria
- James Ford appointed GSK General Counsel
- Roivant subsidiary Dermavant Sciences signs agreement with GSK to purchase rights to tapinarof
GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business
On Tuesday 27 March, we announced that GSK has reached an agreement with Novartis to buyout Novartis’s 36.5% stake in the Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).
The press release is available here and materials from a call for investors and analysts are available below.